The mean value dianabol dosage of systemic clearance ustekinumab following a single intravenous administration to patients with psoriasis ranged from 1.99 to 2.34 ml / day / kg. The average ustekinumab in patients with psoriasis and / or psoriatic arthritis was approximately 3 weeks, and in different studies ranged from 15 to 32 days.
Linearity Systemic exposure ustekinumab in patients with psoriasis introduced proportionally increased after single dose intravenous doses ranging from 0.09 mg / kg to 4.5 mg / kg, and also after a single subcutaneous injection of doses ranging from 24 mg to 240 mg.
Changing ustekinumab concentrations in blood plasma over time after single or repeated injections of multiple drug was generally predictable. The equilibrium concentration of ustekinumab achieved by week 28 in blood plasma in the proposed therapy mode (second injection 4 weeks after the first use, then every 12 weeks). On average, the equilibrium concentration of the drug in patients with psoriasis is 0,21-0,26 mg / ml for a dose of 45 mg and 0,47-0,49 mg / ml for a dose of 90 mg. Accumulation of the drug calum von moger steroids in the serum was not observed during the treatment with a dosage regimen 1 injection every 12 weeks.
Effect of patient body weight on the pharmacokinetics of the drug concentration in blood plasma drug depends on the weight of the patient with psoriasis and / or psoriatic arthritis. When dianabol dosage administered the same dose (45 mg or 90 mg), patients weighing over 100 kg ustekinumab mean concentration in the plasma was less than in patients weighing less than 100 kg. However, the mean minimum plasma concentration ustekinumab patients weighing more than 100 kg, which was administered 90 mg dose was comparable to that in patients weighing less than 100 kg, which was administered 45 mg.
Population pharmacokinetic analyzes Apparent clearance (CL / F) and the volume of distribution (V / F) were 0.465 L / day and 15.7 L, respectively, according to the data obtained in patients with psoriasis. The of the drug was approximately 3 weeks. Gender, age and belonging to this or that race did not influence the apparent clearance of ustekinumab. On the apparent clearance ( drugs affect the body weight of the patients, while patients with a greater value was larger body mass. The average apparent clearance in patients weighing more than 100 kg was about 55% higher than those in patients with less weight. The volume of distributionin patients weighing more than 100 kg was about 37% higher than those in patients with less weight. Similar results were obtained when confirmed by the analysis of population data among patients with psoriatic arthritis.
It was analyzed the influence of comorbid conditions (diabetes, hypertension, hyperlipidemia) on the pharmacokinetics of the drug in patients with psoriasis. In patients with diabetes dianabol dosagevalue was an average of 29% higher than in healthy patients. Population pharmacokinetic analysis showed that there is a tendency of increasing ustekinumab clearance in patients dianabol dosage with a positive immune response.
Special patient groups
Children (12 to 18 years) The pharmacokinetics of ustekinumab in children aged 12 to 18 years, c psoriasis receiving the recommended dose is comparable to the pharmacokinetics in adult patients with psoriasis.
Elderly patients (65 years and older) pharmacokinetics studies in elderly patients have been conducted. The population pharmacokinetic analysis in patients over 65 years of age showed no effect on the magnitude of the apparent clearance and volume of distribution .
Patients with impaired renal function data on the pharmacokinetics of the drug in patients with impaired renal function are not available.
Patients with impaired liver function data on the pharmacokinetics of the drug in patients with impaired liver function no.
Other groups of patients The dianabol dosage of ustekinumab comparable in Asian patients with psoriasis and in patients with non-Asian psoriasis. The use of alcohol or tobacco did not affect the pharmacokinetics of ustekinumab.